A carregar...

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for people who are un...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cochrane Database Syst Rev
Main Authors: Schmidt, Amand F, Carter, John-Paul L, Pearce, Lucy S, Wilkins, John T, Overington, John P, Hingorani, Aroon D, Casas, JP
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2020
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094613/
https://ncbi.nlm.nih.gov/pubmed/33078867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!